The tissue healing technology startup raised the first tranche of the round from backers including Heraeus' medical component subsidiary.
US-based biopharmaceutical company Ankasa Regenerative Therapeutics raised the $8.5m first tranche of its $17m series A round yesterday, securing cash from investors including industrial product maker Heraeus.
Heraeus, which invested through its medical equipment manufacturing subsidiary, Heraeus Medical, was joined by venture capital firm Avalon Ventures, which led the round, and VC fund Correlation Ventures.
Ankasa is developing a stem cell activator that could potentially to speed up tissue healing in a degenerative conditions that affect bone, cartilage, skin, muscle,…
